CN116323578A - 噻吩hsd17b13抑制剂及其用途 - Google Patents

噻吩hsd17b13抑制剂及其用途 Download PDF

Info

Publication number
CN116323578A
CN116323578A CN202180065663.XA CN202180065663A CN116323578A CN 116323578 A CN116323578 A CN 116323578A CN 202180065663 A CN202180065663 A CN 202180065663A CN 116323578 A CN116323578 A CN 116323578A
Authority
CN
China
Prior art keywords
alkyl
heterocycloalkyl
aryl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180065663.XA
Other languages
English (en)
Chinese (zh)
Inventor
约书亚·奥丁戈
萨姆帕斯·库马尔·阿南丹
希瑟·凯·韦伯·许
文森特·弗洛里奥
沙布拉曼亚姆·贾纳德汉·坦特里
阿什赛亚玛尼·杰亚拉吉·杜拉斯瓦米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eni Pharmaceutical Co
Original Assignee
Eni Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eni Pharmaceutical Co filed Critical Eni Pharmaceutical Co
Publication of CN116323578A publication Critical patent/CN116323578A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202180065663.XA 2020-07-24 2021-07-23 噻吩hsd17b13抑制剂及其用途 Pending CN116323578A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063056165P 2020-07-24 2020-07-24
US63/056,165 2020-07-24
US202063113555P 2020-11-13 2020-11-13
US63/113,555 2020-11-13
PCT/US2021/042960 WO2022020714A1 (en) 2020-07-24 2021-07-23 Thiophene hsd17b13 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN116323578A true CN116323578A (zh) 2023-06-23

Family

ID=79729016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180065663.XA Pending CN116323578A (zh) 2020-07-24 2021-07-23 噻吩hsd17b13抑制剂及其用途

Country Status (6)

Country Link
US (1) US12673930B2 (cg-RX-API-DMAC7.html)
EP (1) EP4185381A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537271A (cg-RX-API-DMAC7.html)
CN (1) CN116323578A (cg-RX-API-DMAC7.html)
TW (1) TW202220967A (cg-RX-API-DMAC7.html)
WO (1) WO2022020714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537271A (ja) 2020-07-24 2023-08-31 イニファーム,インク. チオフェンhsd17b13阻害剤とその使用
CN116670118B (zh) 2020-11-13 2026-02-06 伊尼制药公司 二氯苯酚hsd17b13抑制剂及其用途
US12617772B2 (en) 2021-04-05 2026-05-05 Inipharm, Inc. Hydroxypyridine HSD17B13 inhibitors and uses thereof
CA3229569A1 (en) 2021-08-20 2023-02-23 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
CN118647606A (zh) * 2021-12-15 2024-09-13 百时美施贵宝公司 作为rxfp1激动剂的苯并噻吩衍生物
EP4469451A4 (en) * 2022-01-26 2025-12-24 Inipharm Inc HSD17B13 2-SUBSTITUTE THIAZOLES INHIBITORS AND RELATED USES
HRP20251564T1 (hr) * 2022-05-19 2026-01-30 Astrazeneca Ab Amidni heteroaromatski spojevi korisni u liječenju bolesti jetre
US20250340546A1 (en) 2022-06-09 2025-11-06 Boehringer Ingelheim International Gmbh Hsd17b13 inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233246A (zh) * 1996-10-15 1999-10-27 默克专利股份公司 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
US20060217426A1 (en) * 2003-03-27 2006-09-28 Kirin Beer Kabushiki Kaisha Compound inhibiting in vivo phosphorous transport and medicine containing the same
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
US20150119426A1 (en) * 2012-05-04 2015-04-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Modulators of the relaxin receptor 1
CN105524053A (zh) * 2014-10-19 2016-04-27 广东东阳光药业有限公司 四氢苯并噻吩化合物
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
KR20170092126A (ko) * 2016-02-02 2017-08-10 부산대학교 산학협력단 Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도
CN109563070A (zh) * 2016-08-15 2019-04-02 伊莱利利公司 作为napi-iib抑制剂的稠合噻吩衍生物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694711A (en) 1952-12-02 1954-11-16 American Cyanamid Co Quinazolone antimalarial compounds
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
WO2006040966A1 (ja) 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
US20090163521A1 (en) 2005-06-28 2009-06-25 Orchid Research Laboratories Limited Novel Pyrazolopyrimidinone Derivatives
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US8440665B2 (en) 2010-07-02 2013-05-14 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
CA2831978A1 (en) * 2011-03-03 2012-09-07 Universitat Des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
CN103288771B (zh) 2012-02-29 2014-12-03 中国中化股份有限公司 异噻唑类化合物及其作为杀菌剂的用途
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2016081522A1 (en) 2014-11-17 2016-05-26 Rhode Island Hospital Nanomaterial compositions, synthesis, and assembly
EP3404024B1 (en) 2016-01-14 2020-11-18 Kangpu Biopharmaceuticals, Ltd. Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
TWI762634B (zh) * 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
EA202091897A1 (ru) * 2018-02-08 2020-10-27 Энио Фарма Неконденсированные производные тиофена и их применение
US20210000906A1 (en) * 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation
JP2023537271A (ja) 2020-07-24 2023-08-31 イニファーム,インク. チオフェンhsd17b13阻害剤とその使用
CN116194440A (zh) 2020-07-24 2023-05-30 伊尼制药公司 喹唑啉酮hsd17b13抑制剂及其用途
IL299972A (en) 2020-08-05 2023-03-01 Enyo Pharma Thiophane compounds for use in the treatment of renal fibrosis
WO2022040324A1 (en) 2020-08-18 2022-02-24 Metrea Biosciences, Inc. COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13
MX2023003677A (es) 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
US20240083861A1 (en) 2020-09-30 2024-03-14 Fl2022-001, Inc. Hsd17b13 inhibitors and uses thereof
EP4221701A1 (en) 2020-09-30 2023-08-09 FL2022-001, Inc. Hsd17b13 inhibitors and uses thereof
US20230416802A1 (en) 2020-11-06 2023-12-28 Inipharm, Inc. Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatment
CN116670118B (zh) 2020-11-13 2026-02-06 伊尼制药公司 二氯苯酚hsd17b13抑制剂及其用途
EP4319872A4 (en) 2021-04-05 2025-03-12 Inipharm, Inc. Thiazole/isothiazole hsd17b13 inhibitors and uses thereof
US12617772B2 (en) 2021-04-05 2026-05-05 Inipharm, Inc. Hydroxypyridine HSD17B13 inhibitors and uses thereof
CA3229569A1 (en) 2021-08-20 2023-02-23 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
EP4469451A4 (en) 2022-01-26 2025-12-24 Inipharm Inc HSD17B13 2-SUBSTITUTE THIAZOLES INHIBITORS AND RELATED USES
US20250340546A1 (en) 2022-06-09 2025-11-06 Boehringer Ingelheim International Gmbh Hsd17b13 inhibitors
CN118955491A (zh) 2024-09-04 2024-11-15 广东药科大学 一类新型噻唑类hsd17b13抑制剂、其制备方法及其作为药物的用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233246A (zh) * 1996-10-15 1999-10-27 默克专利股份公司 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
US20060217426A1 (en) * 2003-03-27 2006-09-28 Kirin Beer Kabushiki Kaisha Compound inhibiting in vivo phosphorous transport and medicine containing the same
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
US20150119426A1 (en) * 2012-05-04 2015-04-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Modulators of the relaxin receptor 1
CN105524053A (zh) * 2014-10-19 2016-04-27 广东东阳光药业有限公司 四氢苯并噻吩化合物
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
KR20170092126A (ko) * 2016-02-02 2017-08-10 부산대학교 산학협력단 Ppar, fxr 및 ampk 활성화 효능을 갖는 신규 티오펜 화합물 또는 이의 약제학적으로 허용 가능한 염 및 이의 의학적 용도
CN109563070A (zh) * 2016-08-15 2019-04-02 伊莱利利公司 作为napi-iib抑制剂的稠合噻吩衍生物

Also Published As

Publication number Publication date
WO2022020714A1 (en) 2022-01-27
EP4185381A4 (en) 2024-08-21
JP2023537271A (ja) 2023-08-31
US20230278978A1 (en) 2023-09-07
US12673930B2 (en) 2026-07-07
EP4185381A1 (en) 2023-05-31
TW202220967A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
EP4185381A1 (en) Thiophene hsd17b13 inhibitors and uses thereof
CN116670118B (zh) 二氯苯酚hsd17b13抑制剂及其用途
CN116194440A (zh) 喹唑啉酮hsd17b13抑制剂及其用途
WO2021211974A1 (en) Hsd17b13 inhibitors and uses thereof
US12617772B2 (en) Hydroxypyridine HSD17B13 inhibitors and uses thereof
WO2022216627A1 (en) Thiazole/isothiazole hsd17b13 inhibitors and uses thereof
CN119032090A (zh) 2-取代的噻唑hsd17b13抑制剂及其用途
CN107759588A (zh) 一类苯基‑(吡唑并[1,5‑a]吡啶‑3‑基)甲酮衍生物
HK40097014B (en) Dichlorophenol hsd17b13 inhibitors and uses thereof
HK40094120A (en) Quinazolinone hsd17b13 inhibitors and uses thereof
HK40097014A (zh) 二氯苯酚hsd17b13抑制剂及其用途
WO2026064458A1 (en) Hsd17b13 inhibitors and uses thereof
TW202413358A (zh) 用於抑制pkmyt1之化合物及方法
EA049239B1 (ru) Дихлорфенольные ингибиторы hsd17b13 и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095049

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230623